ARS Pharmaceuticals' stock surged 11% on $6.5 million Q4 revenue for Neffy allergy spray

From Investing.com: 2025-01-13 11:58:14

ARS Pharmaceuticals’ stock surged 11% following the announcement of a $6.5 million fourth-quarter net revenue for Neffy allergy spray, surpassing analyst estimates. Total net product sales in 2024 reached $7.1 million after the product became available to wholesalers and pharmacies in September. The company aims to increase demand and target prescribers in 2025.



Read more at Investing.com: ARS Pharmaceuticals shares surge on strong Q4 revenue for allergy spray By Investing.com